Pharma firms must stay healthy to win vaccine race
India companies have slim chance of success without government or donor funding, but stocks surge is a good sign as they rush to find cure for Covid-10 pandemic.
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
THE race to produce a vaccine against the novel coronavirus is featuring five Indian multinational pharmaceuticals and biotech companies and two research institutes that are aiming to deliver vaccines and super drugs at prices much below their global counterparts. So far, more than 40 companies across the world are scrambling to find a cure for the pandemic.
Indian pharma companies - which have a long tradition of producing low-cost lifesaving drugs - are working with great speed to find a breakthrough vaccine. To encourage them, India's regulatory Central Drugs Standard Control Organisation announced on March 20 that it was relaxing some standards in order to fast-track the regulatory approval process for vaccines designed to prevent or treat Covid-19.
Intense research is underway across India. Zydus Cadila Ltd is working with the Serum Institute of India (SII). Bharat Biotech Ltd is collaborating with international university researchers.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Vietnam acts fast to shield firms, households from fuel price surge
Beijing’s calculated silence on the Iran war
S-E Asia tourism takes hit from Middle East crisis, but intra-regional travel could spell hope
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
